ATRC News and Press, AtriCure Inc. From 07/25/23

Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvem...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 2...

2023-06-14 15:43:15 ET Summary AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales multiples. While this combination is attractive, I ...

2023-05-29 04:56:42 ET Summary Cryoport continues to grow its top line, while bottom line results are improving. The picture isn't as positive as it initially appears, but progress is still very much welcomed. Even so, the firm still has problems and shares look far too pricey...

2023-05-02 21:40:06 ET AtriCure, Inc. (ATRC) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Marissa Bych – Vice President-Gilmartin Group Mike Carrel – President and Chief Executive Officer Angie Wirick – Chief F...

2023-05-02 16:17:26 ET AtriCure press release ( NASDAQ: ATRC ): Q1 Non-GAAP EPS of -$0.23 beats by $0.12 . Revenue of $93.5M (+25.4% Y/Y) beats by $5.97M . 2023 Financial Guidance Full year 2023 revenue is projected to be $385 million to $392 million vs $38...

Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improveme...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an investor education webcast in conjunction ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, ...